JP2024029009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024029009A5 JP2024029009A5 JP2023212944A JP2023212944A JP2024029009A5 JP 2024029009 A5 JP2024029009 A5 JP 2024029009A5 JP 2023212944 A JP2023212944 A JP 2023212944A JP 2023212944 A JP2023212944 A JP 2023212944A JP 2024029009 A5 JP2024029009 A5 JP 2024029009A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- small cell
- lung cancer
- mdm2 inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17165111.0 | 2017-04-05 | ||
| EP17165111 | 2017-04-05 | ||
| EP17197930.5 | 2017-10-24 | ||
| EP17197930 | 2017-10-24 | ||
| PCT/EP2018/058562 WO2018185135A1 (en) | 2017-04-05 | 2018-04-04 | Anticancer combination therapy |
| JP2019554792A JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554792A Division JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024029009A JP2024029009A (ja) | 2024-03-05 |
| JP2024029009A5 true JP2024029009A5 (https=) | 2024-03-25 |
Family
ID=61899297
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554792A Ceased JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
| JP2023212944A Pending JP2024029009A (ja) | 2017-04-05 | 2023-12-18 | 抗がん併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554792A Ceased JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200101079A1 (https=) |
| EP (2) | EP3606556A1 (https=) |
| JP (2) | JP2020516604A (https=) |
| KR (2) | KR20190132687A (https=) |
| CN (2) | CN110505884B (https=) |
| AU (1) | AU2018248586A1 (https=) |
| BR (1) | BR112019021032A2 (https=) |
| CA (1) | CA3057558A1 (https=) |
| CL (2) | CL2019002800A1 (https=) |
| MX (1) | MX2019011945A (https=) |
| PH (1) | PH12019502291A1 (https=) |
| WO (1) | WO2018185135A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| WO2017055404A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
| JP7066696B2 (ja) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | 抗ｌａｇ－３抗体及びその使用方法 |
| MY201482A (en) | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| EP4516809A3 (en) | 2017-04-05 | 2025-09-03 | F. Hoffmann-La Roche AG | Bispecific antibodies specifically binding to pd1 and lag3 |
| TWI791794B (zh) * | 2018-03-20 | 2023-02-11 | 瑞士商諾華公司 | 藥物組合 |
| US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2020030016A1 (en) * | 2018-08-08 | 2020-02-13 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of immunotherapies with mdm2 inhibitors |
| CN117338800A (zh) * | 2018-11-01 | 2024-01-05 | 阿尔法陶医疗有限公司 | 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活 |
| WO2020123656A1 (en) * | 2018-12-11 | 2020-06-18 | Kartos Therapeutics | Methods and compositions of treating an ophthalmic condition |
| AU2022326796A1 (en) | 2021-08-09 | 2024-01-18 | Boehringer Ingelheim International Gmbh | Oral composition comprising a mdm2-antagonist for cancer therapy |
| CN115089585A (zh) * | 2022-08-05 | 2022-09-23 | 中国科学院大学宁波华美医院 | Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用 |
| US20240217985A1 (en) * | 2022-12-22 | 2024-07-04 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORM OF AN MDM2-p53 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS |
| WO2024238404A2 (en) * | 2023-05-12 | 2024-11-21 | Pmv Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BRPI0713119A2 (pt) | 2006-06-30 | 2012-04-17 | Schering Corp | piperidinas substituìdas que aumentam a atividade de p53 e os usos destas |
| EA200901212A1 (ru) | 2007-03-29 | 2010-04-30 | Новартис Аг | 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AR073578A1 (es) | 2008-09-15 | 2010-11-17 | Priaxon Ag | Pirrolidin-2-onas |
| JP5844159B2 (ja) * | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| JP6595458B2 (ja) | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| WO2015155332A1 (en) | 2014-04-11 | 2015-10-15 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors |
| WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| RS59111B1 (sr) * | 2014-08-21 | 2019-09-30 | Boehringer Ingelheim Int | Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| EP3233918A1 (en) * | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| WO2016205566A1 (en) * | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| HRP20211058T8 (hr) * | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| KR20240158360A (ko) * | 2015-10-09 | 2024-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체 |
| RS61510B1 (sr) * | 2016-05-18 | 2021-03-31 | Boehringer Ingelheim Int | Anti pd-1 i anti-lag3 antitela za lečenje kancera |
| WO2019063802A1 (en) * | 2017-09-29 | 2019-04-04 | Boehringer Ingelheim International Gmbh | ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1 |
-
2018
- 2018-04-04 WO PCT/EP2018/058562 patent/WO2018185135A1/en not_active Ceased
- 2018-04-04 EP EP18715685.6A patent/EP3606556A1/en not_active Withdrawn
- 2018-04-04 MX MX2019011945A patent/MX2019011945A/es unknown
- 2018-04-04 EP EP24157330.2A patent/EP4368200A3/en not_active Withdrawn
- 2018-04-04 BR BR112019021032-6A patent/BR112019021032A2/pt unknown
- 2018-04-04 AU AU2018248586A patent/AU2018248586A1/en not_active Abandoned
- 2018-04-04 CA CA3057558A patent/CA3057558A1/en active Pending
- 2018-04-04 CN CN201880023850.XA patent/CN110505884B/zh not_active Expired - Fee Related
- 2018-04-04 CN CN202210548008.6A patent/CN114949228A/zh active Pending
- 2018-04-04 KR KR1020197032689A patent/KR20190132687A/ko not_active Ceased
- 2018-04-04 JP JP2019554792A patent/JP2020516604A/ja not_active Ceased
- 2018-04-04 KR KR1020247017327A patent/KR20240090927A/ko active Pending
- 2018-04-04 US US16/500,572 patent/US20200101079A1/en not_active Abandoned
-
2019
- 2019-10-01 CL CL2019002800A patent/CL2019002800A1/es unknown
- 2019-10-04 PH PH12019502291A patent/PH12019502291A1/en unknown
-
2022
- 2022-07-15 US US17/812,735 patent/US20230025452A1/en not_active Abandoned
-
2023
- 2023-10-02 CL CL2023002946A patent/CL2023002946A1/es unknown
- 2023-12-18 JP JP2023212944A patent/JP2024029009A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024029009A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2021155426A5 (https=) | ||
| JP6761852B2 (ja) | がん治療 | |
| JP2024133474A5 (https=) | ||
| WO2010081817A1 (en) | Method for treating colorectal cancer | |
| EP4322941A1 (en) | Combination comprising ribociclib and amcenestrant | |
| JP2020502261A5 (https=) | ||
| JP2021526138A5 (https=) | ||
| JP2023527542A5 (https=) | ||
| AU2021227007A1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| JP2019508476A5 (https=) | ||
| RU2011146339A (ru) | Комбинированная терапия с использованием агента (ов) против igfr и специфических ингибиторов igf-1r | |
| JP2023531675A5 (https=) | ||
| JP2022514561A5 (https=) | ||
| EA006295B1 (ru) | Применение производных дистамицина для противоопухолевой терапии | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| JP2023531930A5 (https=) | ||
| JP2020535180A5 (https=) | ||
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| JP2024503379A5 (https=) | ||
| CN1302777C (zh) | 包括取代的丙烯酰偏端霉素衍生物和放射治疗的抗肿瘤联合疗法 | |
| US20240173323A1 (en) | Combination therapy for cancer treatment | |
| US9757396B2 (en) | Method for treating recurring skin and mucous membrane diseases caused by HSV-1 and HSV-2 |